Crossmark

Registry-based study in people with cystic fibrosis and an <i>R117H</i> variant treated with ivacaftor

Crossref DOI link: https://doi.org/10.1136/bmjresp-2022-001447

Published Online: 2023-05-25

Published Print: 2023-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Higgins, Mark

Farietta, Thalia

Campbell, Daniel

Liu, Meng

Ostrenga, Josh

Elbert, Alexander

Shih, Judy

Volkova, Nataliya
Funding

Funding for this research was provided by:

Vertex Pharmaceuticals (Not applicable)
License Information

License valid from 2023-05-25